- Home
- BQ vs TOVX Comparison
BQ vs TOVX Comparison
Compare BQ & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BQ | TOVX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.3M |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BQ | TOVX |
|---|---|---|
| Price | $2.12 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8M | ★ 3.1M |
| Earning Date | 07-21-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,617,102.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.62 | $0.17 |
| 52 Week High | $56.10 | $2.08 |
Technical Indicators
Market Signals| Indicator | BQ | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 41.52 |
| Support Level | $2.00 | $0.17 |
| Resistance Level | $2.30 | $0.22 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 16.45 | 33.10 |
Price Performance
Historical ComparisonAbout BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.